Member Info for TonyFawcett

The BOD’s have written in the Sand, we should at least hold our nerve and see what news comes before the end of first quarter ‘19. Let’s hope the news flow improves next year increasing the SP to boot .

Last nights presentation certainly has lifted my confidence, it’s the update we have been waiting on hopefully we should see a positive response in the share price.

Thanks for going from me as well Cream, and your update. Fingers crossed 🤞

Cream,
I am sorry for directing my frustration at you, but I could have retired on my original investment, I am getting tired of being fobbed off. It’s always Jam tomorrow, unfortunately it has never materialised and my patience is wearing a little thin. I have lost so much money I may as well stay in for the long haul and hope for the best. Luckily other investments have done well.

True Tozerk,
Their credibility is so thin we could all sink, but what I have left of my investment I may as well stay for the test of time .
However I noticed that no timescale has been predicted so the risk remains IMO

Sounds positive but more Jam tomorrow, but we’ve been here for the long haul we Maya’s well stay it ou. Hopefully this news should have a positive effect on the SP tomorrow, it’s a game of trust and patience.

The only reason we’re still here is that we are hopeful of getting some of our investment back, yes AIM shares are risky , very risky. They are also news sensitive, and with no substantiated news then they will drift lower.

If the BOD are withholding price sensitive information, good or bad, then I am sure they are aware of Stockmarket rules. Six months ago they announced they were in advanced talks on 401, I don’t believe I understand the meaning of advanced anymore, one can only assume that talks have either stalled or collapsed, this in itself is price sensitive information. We deserve an update as to wether talks are on going and if so what is the hold up ?

The Investors Presentation is not until 6pm, it’s entirely possible we could expect an RNS after market close. Without an update how will they attract further investment when their integrity is blown to bits and their credibility shot to pieces.
Their track record for investor return is either comical or Corporate Fraud.

I wonder what story they are going to concoct for potential investors today, I really thought this would coincide with a major announcement this morning. For Directors to announce earlier in the year that VAL was going through an exiting period, I think Enid Blyton could matched them on this one. As like others on here I have lost most of my investment and now we must challenge the BOD to come clean and admit talks on 401 have stalled.

I am surprised that there was not a RNS this morning, how else are VAL going to attract new investors to turn up to tomorrow’s Investor Presentation when this Jam tomorrow companies credibility is wearing so thin. If anyone is attending tomorrow’s presentation then the BOD’s integrity has to be questioned as to if they have mislead shareholders.

There’s so much Jam tomorrow with VAL it should be re named ‘ Hartleys ‘

The SP Spread is so wide it neither encourages buyers or sellers.

Despite the SP, I drove past the Woodsmith Mine on Saturday and it seems to be full Steam ahead. It topped up my confidence levels , the share price is too low now as everything seems to be either ahead or on Schedule. As has always been the case this is a very Professional Company that knows where it is heading. With Banks letters of intent due anytime now and Stage 2 financing to be finalised by end of first quarter 19. IMO we can expect a sharp rise in the Share price over the next month or two.

Roll on Thursday, BOD need to pull more than a Rabbit out of the bag to get and keep Investor Support.

Imfinzi is among a trio of new cancer drugs in Astrazeneca’s portfolio. It delivered $371 million of sales in its third quarter, boosting product sales by 9 per cent to $5.3 billion.

Not an insignificant amount for a Cancer Drug, just shows that potential when it comes, if it comes, VAL 401

Just grasping at straws Tozerk

Your underselling yourself surely. I would advise you to alert them as to your availability soon so they can factor you in in their next fund raising.

Could Astrazeneca be a possible Buyer of VAL in its search for a wonder cancer treatment drug?

Save
A big lung cancer trial at Astrazeneca has failed, delivering a setback for the pharmaceuticals company’s attempts to rebuild its drug pipeline.

Latest results from a late-stage clinical trial called Mystic showed that Imfinzi, the drug, did not improve overall survival rates compared with chemotherapy in patients with the most advanced form of the disease.

Mystic had become one of the most closely followed oncology trials, viewed as a symbol of the potential of Astrazeneca’s emerging drugs portfolio and as important to its future as an independent company.

However, its significance has diminished since July last year, when, after earlier results from the Mystic trial also disappointed, City analysts began to cut forecasts.

The importance of Mystic to the Anglo-Swedish company’s prospects has also lessened since it unveiled a series of successful clinical trial results and market launches, including in its cancer portfolio.

The potential new blockbusters in Astrazeneca’s pipeline have helped to put it on course to return to product sales growth for the first time in four years as it recovers from generic competition and diminished sales from old bestsellers, particularly Crestor, its anti-cholesterol statin.

Astrazeneca is based in Cambridge and is one of Britain’s leading pharmaceuticals companies, valued at about £79 billion on the London stock market.

Progress since the first Mystic setback last year had been a big boost for Pascal Soriot, the chief executive since 2012, who put Astrazeneca’s research and development at the heart of the company’s defence against a hostile takeover approach four years ago from Pfizer, an American rival. Mr Soriot reiterated last week that Astrazeneca was on track to deliver annual sales of more than $40 billion by 2023, a target that he set during the takeover battle.

Shares in Astrazeneca fell 113p, or 1.8 per cent, to £62.04 yesterday, but they remain up by a fifth this year, outperforming the premier share index and comfortably above the £55-per-share price that Pfizer offered.

The phase III Mystic trial was studying Imfinzi as a monotherapy and in combination with another drug against chemotherapy in previously untreated patients with stage IV metastatic non-small cell lung cancer. The study did not meet the primary target of improving overall survival compared with chemotherapy.

Sean Bohen, chief medical officer of Astrazeneca, said that the company was “disappointed that these results missed statistical significance”, but added: “We remain confident in Imfinzi as the cornerstone of our immuno-oncology programme and continue to evaluate its potential in ongoing non-small cell lung cancer trials, including Imfinzi and Imfinzi plus tremelimumab in combination with chemotherapy.”

Imfinzi is among a trio of new cancer drugs in Astrazeneca’s portfolio. It delivered $371 million of sales in its third quarter, boosting product sales by 9 per cent to $5.3 billion. It has be